标题
Improved Endpoints for Cancer Immunotherapy Trials
作者
关键词
-
出版物
JNCI-Journal of the National Cancer Institute
Volume 102, Issue 18, Pages 1388-1397
出版商
Oxford University Press (OUP)
发表日期
2010-09-09
DOI
10.1093/jnci/djq310
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Developing Immunotherapy As Legitimate Therapy for Patients With Prostate Cancer
- (2010) Eric J. Small et al. JOURNAL OF CLINICAL ONCOLOGY
- Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium
- (2009) Cedrik Michael Britten et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells
- (2009) Sylvia Janetzki et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
- (2009) J. Weber et al. CLINICAL CANCER RESEARCH
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Improving the efficacy of cancer immunotherapy
- (2009) J. Copier et al. EUROPEAN JOURNAL OF CANCER
- “MIATA”—Minimal Information about T Cell Assays
- (2009) Sylvia Janetzki et al. IMMUNITY
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group
- (2008) Alessandro Testori et al. JOURNAL OF CLINICAL ONCOLOGY
- New Response Criteria Proposed for Immunotherapies
- (2008) Rabiya S. Tuma JNCI-Journal of the National Cancer Institute
- An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial
- (2008) Christopher Wood et al. LANCET
- Cancer Immunology
- (2008) Olivera J. Finn NEW ENGLAND JOURNAL OF MEDICINE
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
- (2008) F. S. Hodi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS
- (2008) F Stephen Hodi et al. Nature clinical practice. Oncology
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started